AT DIAGNOSIS • DETECT
India’s only MD (Medical Device)-9 CDSCO-approved blood test for circulating tumour cell (CTC) detection.
Learn more →
BEFORE THERAPY • PROFILE
DNA and RNA sequencing to identify SNVs, CNVs, fusions, TMB, MSI and HRD across four panels.
DURING TREATMENT • MONITOR
Tumor-informed ctDNA tracking with CTC analysis at serial time points to follow response and progression.
Leading institutions use
the OncoDiscover®
OncoDiscover® tests are being widely accepted by the oncology fraternity and is used for monitoring and effective therapy decisions.
.jpg)
OncoDiscover® CTC
Applicable across 15+ cancer types: Bladder, Breast, Cervical, Colorectal, Esophageal, Gallbladder, GI, Head & Neck, Lung, Ovarian, Pancreatic, Prostate, Kidney, Testicular & Thyroid.
OncoDiscover® CTC + PD-L1
Applicable across 15+ cancer types: Bladder, Breast, Cervical, Colorectal, Esophageal, Gallbladder, GI, Head & Neck, Lung, Ovarian, Pancreatic, Prostate, Kidney, Testicular & Thyroid.
OncoDiscover® CTC + HER-2
Applicable to cancers of the Breast, Colorectal, Gallbladder, Gastrointestinal, Head & Neck, Lung, Prostate and Thyroid.
OncoDiscover® CTC + EGFR
Detect and monitor CTCs and EGFR expression to gain insights into tumor biology, disease progression, and treatment response in NSCLC and lung cancer.
OncoDiscover® CTC + AR-V7
Characterize AR-V7–positive CTCs in real time to uncover molecular signals associated with treatment resistance and better understand the evolving biology of advanced prostate cancer.
OncoDiscover® EMT CTC
This test monitors CTCs expressing epithelial (EpCAM, CK) and mesenchymal (vimentin) markers, associated with increased mobility, invasion, metastasis, and therapy resistance.
Accreditations/ Patents
Medical Device - 9 CDSCO Approved Test
License No.
MFG/IVD/2019/000031
ISO 13485:2016
Certified Lab
Certified by INTERTEK;
Certificate No. 0140783
NABL Accredited Lab
Certificate No.
NABLM0726MH08160
Globally Patented
International Application No.
PCT/IB2016/050779
Our
Publications
In collaboration with researchers and thought leaders around the world, OncoDiscover® Team combines scientific expertise with cutting-edge innovation to advance the frontiers of cancer care. The research behind the technology is supported by 100+ scientific publications presented at leading global forums such as ASCO, AACR, ESMO, ISLB, etc
1 Sept 2026
Longitudinal Assessment of Circulating Tumor Cells Expressing PD-L1 and Clusters in Esophageal Cancer Patients
A longitudinal study of 110 esophageal cancer patients evaluated CTCs, PD-L1 expression, and CTC clusters, highlighting their potential as predictive biomarkers for treatment outcomes and occult minimal cellular residual disease.
30 Aug 2026
Evaluation of circulating tumor cells expressing PD-L1 and CTC clusters at baseline and follow ups in triple-negative breast cancer
A retrospective study of 180 TNBC blood samples evaluated CTC burden, PD-L1 expression and CTC clusters using the CDSCO-approved OncoDiscover platform, highlighting their potential for longitudinal disease monitoring and biomarker-guided management.
30 Aug 2026
Assessment of apprehension for Minimal Cellular Residual Disease Using Circulating Tumour Cells in Pre and Post Surgery Breast Cancer Patients
A prospective study evaluates RUPIKA, a structured CTC-based MRD disclosure protocol, showing significantly reduced cancer worry among breast cancer patients after surgery compared with routine result communication.
Be informed.
Be a fighter.
Sharvari Pantekar
Breast Cancer Survivor
Rupali Gunjikar
Neuro-endocrine Cancer Survivor
What’s More Painful than a Cancer Relapse
A cancer Relapse not Caught in Time.
14 Mar 2026
Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control
Actorius Innovations and Research Pvt Ltd, a pioneering Indo-US biotechnology company revolutionizing oncology through advanced circulating tumor cell (CTC) technologies, continues to make significant strides under the visionary leadership of Dr. Jayant Khandare, Founder, Managing Director, and Chief Scientific Officer.
